Ignite Creation Date:
2025-12-25 @ 1:09 AM
Ignite Modification Date:
2026-01-03 @ 6:47 PM
Study NCT ID:
NCT04566393
Status:
AVAILABLE
Last Update Posted:
2024-09-23
First Post:
2020-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Sponsor:
xCures
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
| None | Small Bowel Cancer | View |
| None | Colorectal Cancer | View |
| None | Melanoma | View |
| None | Non Small Cell Lung Cancer | View |
| None | Thyroid Cancer | View |
| None | Bladder Cancer | View |
| None | Head and Neck Cancer | View |
| None | Gastric Cancer | View |
| None | Esophageal Cancer | View |
| None | Cholangiocarcinoma | View |
| None | Ovarian Cancer | View |
| None | Hepatocellular Carcinoma | View |
| None | Glioblastoma | View |
| None | MAPK Gene Mutation | View |
| None | KRAS Activating Mutation | View |
| None | BRAF Gene Mutation | View |
| None | NRAS Gene Mutation | View |
| None | HRAS Gene Mutation | View |
| None | MEK Mutation | View |
| None | ERK Mutation | View |
Keywords: